Indoco Remedies Ltd Sees Bullish Technical Momentum Amid Mixed Long-Term Returns

Technical Momentum Gains Traction

Indoco Remedies Ltd (stock code 601817), operating within the Pharmaceuticals & Biotechnology sector, has experienced a significant price movement recently. The stock closed at ₹273.75, up 12.89% from the previous close of ₹242.50, with intraday highs reaching ₹287.35. This surge has pushed the stock closer to its 52-week high of ₹332.15, a notable recovery from its 52-week low of ₹163.70.

The technical trend has upgraded from mildly bullish to bullish, signalling increased buying interest and positive price momentum. This shift is supported by several key indicators. The Moving Average Convergence Divergence (MACD) on the weekly chart is firmly bullish, while the monthly MACD remains mildly bullish, suggesting sustained upward momentum over both short and medium terms.

Meanwhile, the Relative Strength Index (RSI) on both weekly and monthly timeframes currently shows no definitive signal, indicating the stock is neither overbought nor oversold. This neutral RSI reading suggests room for further price appreciation without immediate risk of a reversal due to overextension.

Moving Averages and Bollinger Bands Confirm Uptrend

Daily moving averages have turned bullish, reinforcing the positive price action. The stock price trading above key moving averages typically signals a healthy uptrend, attracting momentum traders and institutional interest. Complementing this, Bollinger Bands on both weekly and monthly charts are bullish, indicating that price volatility is supporting the upward trend without excessive deviation.

However, the Know Sure Thing (KST) indicator presents a mixed picture: bullish on the weekly timeframe but bearish on the monthly. This divergence suggests that while short-term momentum is strong, longer-term momentum may be facing some headwinds or consolidation phases.

Volume and Dow Theory Trends

On-Balance Volume (OBV) readings show no clear trend on weekly or monthly charts, implying that volume has not decisively confirmed the price moves. This lack of volume confirmation warrants caution, as strong price moves without volume support can be vulnerable to reversals.

Dow Theory assessments remain mildly bullish on both weekly and monthly scales, aligning with the overall positive technical outlook but signalling that the trend is not yet robust enough to be classified as strongly bullish.

Performance Comparison with Sensex

Indoco Remedies has outperformed the Sensex significantly over recent short-term periods. The stock delivered a 14.61% return over the past week compared to the Sensex’s decline of 1.17%. Over the last month, the stock surged 24.69%, while the benchmark index fell 1.95%. Year-to-date, Indoco Remedies posted a 16.59% gain, contrasting with the Sensex’s 10.15% loss.

However, longer-term returns paint a more cautious picture. Over one year, the stock declined 1.12%, slightly underperforming the Sensex’s 4.48% drop. Over three and five years, Indoco Remedies has lagged considerably, with returns of -12.23% and -43.66% respectively, while the Sensex gained 17.10% and 32.35% over the same periods. The 10-year return also remains negative at -15.21%, compared to the Sensex’s robust 168.37% growth.

Mojo Score and Grade Reflect Caution

Despite the recent technical improvements, the company’s MarketsMOJO score remains low at 40.0, with a mojo grade of Sell. This is an upgrade from a previous Strong Sell rating as of 28 August 2026, indicating some improvement in outlook but still signalling caution for investors. The small-cap classification further emphasises the stock’s higher risk profile relative to larger, more stable pharmaceutical peers.

Investors should weigh the bullish technical signals against the fundamental and market context, including the company’s mixed long-term performance and modest mojo score.

Technical Indicators: A Mixed but Improving Picture

The bullish MACD and moving averages suggest that momentum traders may find opportunities in the near term. The neutral RSI readings imply that the stock is not yet overbought, allowing room for further gains. However, the bearish monthly KST and lack of volume confirmation via OBV highlight potential risks of a pullback or consolidation.

Traders should monitor key support levels near ₹241.30 (today’s low) and resistance around ₹287.35 (today’s high) and the 52-week high of ₹332.15. A sustained break above these levels could confirm a stronger uptrend, while failure to hold support may signal a return to sideways or bearish conditions.

Investor Takeaway

Indoco Remedies Ltd’s recent technical upgrades signal a potential shift in market sentiment, with bullish momentum gaining ground. The stock’s strong short-term returns relative to the Sensex and positive MACD and moving average signals provide a foundation for cautious optimism.

Nevertheless, the company’s modest mojo score, small-cap status, and mixed longer-term performance suggest that investors should remain vigilant. The absence of volume confirmation and bearish monthly KST indicator warrant careful monitoring of price action and technical levels.

For investors considering exposure to the Pharmaceuticals & Biotechnology sector, Indoco Remedies offers an intriguing but nuanced opportunity. Balancing technical momentum with fundamental risks will be key to navigating this stock’s evolving landscape.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →